Gracewell

Gracewell (Shanghai) Biotechnology is a clinical-stage biotechnology company focused on developing next-generation oncolytic virus therapies for cancer. The company utilizes its proprietary Oncolytic Virus Platform (OVP) to engineer viruses that selectively infect and lyse tumor cells while stimulating a systemic anti-tumor immune response. Its lead candidate, OVP-01, is an engineered herpes simplex virus type 1 (oHSV-1) currently being evaluated in Phase 1 clinical trials for the treatment of recurrent glioblastoma. Gracewell's technology aims to overcome the limitations of first-generation oncolytic viruses by enhancing viral potency and improving delivery within the tumor microenvironment. Founded by industry veterans with extensive experience in viral immunotherapy, the company is backed by prominent venture capital firms including Sherpa Healthcare Partners and Decheng Capital.